alexa Onco-cardiology: A Multidisciplinary Approach To Improving Cardiovascular Outcomes Of Cancer Survivors
ISSN: 2155-9880

Journal of Clinical & Experimental Cardiology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

36th Cardiovascular Nursing & Nurse Practitioners Meeting
July 10-11, 2017 Chicago, USA

Jean-Bernard Durand
St. Luke's Episcopal Hospital, USA
Posters & Accepted Abstracts: J Clin Exp Cardiolog
DOI: 10.4172/2155-9880-C1-075
Abstract
The United States has over 18 million cancer survivors the most likely event faced by these vulnerable patients are recurrence of malignancy or a new primary cancer, followed by a cardiovascular event. Anti-cancer therapy has made great progress at the start of the 21st century from multi-targeted therapies to targeted therapies and immunotherapy to treat solid and liquid tumors. The majority of patients whom have completed anti-cancer therapy continue their follow-up strictly in oncology centers. Cardioncology programs are rapidly developing within the United States and throughout the world in order to meet the needs of an expanding cancer survivorship from improved outcomes of anticancer therapy. The most common cardiovascular complications from anticancer therapy includes: Congestive heart failure, hypertension and QTC prolongation. In conjunction with radiation therapy, valvular disease and pericardial disease as well as ischemic heart disease can be challenging to diagnose and treat in cancer patients. There are limited randomized placebo controlled trials that have been conducted which demonstrates improved outcomes of cancer survivors most studies have been retrospective in nature therefore a great deal of practice based guidelines have been incorporated into cardio oncology clinics. Cancer patients have largely been excluded from cardiovascular clinical trials, and cardiovascular patients have been largely excluded from cancer trials. Both U S and European have largely been the result of consensus statements and modifications of current ACC, AHA, HF SA, ASCO. The use of standard of care therapy in patients with left ventricular systolic dysfunction, hypertension, and valvular disease has greatly improved the outcomes of cancer survivors.
Biography

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords